Oxford Nanopore prevails against PacBio in final decision by US Court of Appeal that upholds ITC ruling

– Decision defeats attempts by PacBio to prevent Oxford Nanopore from
selling its technology in the US –

OXFORD, England–(BUSINESS WIRE)–Oxford Nanopore announces that the US Court of Appeals for the Federal
Circuit today upheld the decision of the International Trade Commission
(ITC) in favour of Oxford Nanopore. In a complaint previously filed by
Pacific Biosciences, the ITC had previously ruled that the patents being
asserted against Oxford Nanopore with claims directed towards a method
of single molecule sequencing were limited to template-dependent
synthesis.

The decision was also consistent with a recent decision by the European
Patent Office to revoke Pacific Biosciences’ patent EP3045542 with
claims to a single molecule sequencing process.

“Pacific Biosciences has not succeeded in its strategy to try to
prevent us from selling our real-time, direct sequencing technology,
that can provide a full range of solutions from field-based sequencing
to terabases of ultra long reads in a lab,
” said Gordon Sanghera,
CEO.

The court issued a Rule 36 judgement, which is a unanimous confirmance
of the ITC findings.

Contacts

Oxford Nanopore
Zoe McDougall
media@nanoporetech.com
Website:
https://nanoporetech.com/
Twitter
@nanopore
WeChat: nanoporetech